GENMAB A/S -SP ADR (GMAB)
US3723032062 - ADR
Taking everything into account, GMAB scores 7 out of 10 in our fundamental rating. GMAB was compared to 588 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes GMAB very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year GMAB was profitable.
In the past year GMAB had a positive cash flow from operations.
GMAB had positive earnings in each of the past 5 years.
Each year in the past 5 years GMAB had a positive operating cash flow.
1.2 Ratios
GMAB has a better Return On Assets (12.33%) than 97.95% of its industry peers.
With an excellent Return On Equity value of 13.77%, GMAB belongs to the best of the industry, outperforming 96.93% of the companies in the same industry.
With an excellent Return On Invested Capital value of 12.63%, GMAB belongs to the best of the industry, outperforming 97.44% of the companies in the same industry.
GMAB had an Average Return On Invested Capital over the past 3 years of 13.32%. This is in line with the industry average of 13.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.33% | ||
| ROE | 13.77% | ||
| ROIC | 12.63% |
ROA(3y)14.15%
ROA(5y)15.85%
ROE(3y)15.69%
ROE(5y)17.48%
ROIC(3y)13.32%
ROIC(5y)15.82%
1.3 Margins
The Profit Margin of GMAB (26.42%) is better than 98.63% of its industry peers.
GMAB's Profit Margin has declined in the last couple of years.
GMAB has a Operating Margin of 32.30%. This is amongst the best in the industry. GMAB outperforms 98.98% of its industry peers.
GMAB's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 98.63%, GMAB belongs to the top of the industry, outperforming 98.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.3% | ||
| PM (TTM) | 26.42% | ||
| GM | 98.63% |
OM growth 3Y-19.72%
OM growth 5Y-6.68%
PM growth 3Y-17.51%
PM growth 5Y-11.5%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
Compared to 1 year ago, GMAB has about the same amount of shares outstanding.
GMAB has more shares outstanding than it did 5 years ago.
GMAB has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 23.97 indicates that GMAB is not in any danger for bankruptcy at the moment.
GMAB has a better Altman-Z score (23.97) than 94.03% of its industry peers.
The Debt to FCF ratio of GMAB is 0.11, which is an excellent value as it means it would take GMAB, only 0.11 years of fcf income to pay off all of its debts.
GMAB has a Debt to FCF ratio of 0.11. This is amongst the best in the industry. GMAB outperforms 97.44% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that GMAB is not too dependend on debt financing.
The Debt to Equity ratio of GMAB (0.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.11 | ||
| Altman-Z | 23.97 |
ROIC/WACC1.81
WACC6.99%
2.3 Liquidity
GMAB has a Current Ratio of 13.34. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 13.34, GMAB belongs to the top of the industry, outperforming 87.37% of the companies in the same industry.
A Quick Ratio of 13.32 indicates that GMAB has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 13.32, GMAB belongs to the best of the industry, outperforming 87.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.34 | ||
| Quick Ratio | 13.32 |
3. Growth
3.1 Past
GMAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.06%.
The Earnings Per Share has been growing by 22.70% on average over the past years. This is a very strong growth
Looking at the last year, GMAB shows a quite strong growth in Revenue. The Revenue has grown by 12.87% in the last year.
GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.35% yearly.
EPS 1Y (TTM)-21.06%
EPS 3Y-2.95%
EPS 5Y22.7%
EPS growth Q2Q10.26%
Revenue 1Y (TTM)12.87%
Revenue growth 3Y17.67%
Revenue growth 5Y40.35%
Revenue growth Q2Q-10.5%
3.2 Future
The Earnings Per Share is expected to grow by 31.70% on average over the next years. This is a very strong growth
Based on estimates for the next years, GMAB will show a quite strong growth in Revenue. The Revenue will grow by 18.76% on average per year.
EPS Next Y25.53%
EPS Next 2Y28.91%
EPS Next 3Y28.07%
EPS Next 5Y31.7%
Revenue Next Year20.28%
Revenue Next 2Y19.51%
Revenue Next 3Y18.21%
Revenue Next 5Y18.76%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 28.83, which means the current valuation is very expensive for GMAB.
Based on the Price/Earnings ratio, GMAB is valued cheaply inside the industry as 95.56% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 24.55, GMAB is valued at the same level.
A Price/Forward Earnings ratio of 22.87 indicates a rather expensive valuation of GMAB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 95.90% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.92, GMAB is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.83 | ||
| Fwd PE | 22.87 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaply inside the industry as 96.25% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 97.27% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.87 | ||
| EV/EBITDA | 15.92 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of GMAB may justify a higher PE ratio.
GMAB's earnings are expected to grow with 28.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.13
PEG (5Y)1.27
EPS Next 2Y28.91%
EPS Next 3Y28.07%
5. Dividend
5.1 Amount
No dividends for GMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENMAB A/S -SP ADR
NASDAQ:GMAB (5/2/2024, 2:53:07 PM)
27.681
-1.07 (-3.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap17.99B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.83 | ||
| Fwd PE | 22.87 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.13
PEG (5Y)1.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.33% | ||
| ROE | 13.77% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 32.3% | ||
| PM (TTM) | 26.42% | ||
| GM | 98.63% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.34 | ||
| Quick Ratio | 13.32 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-21.06%
EPS 3Y-2.95%
EPS 5Y
EPS growth Q2Q
EPS Next Y25.53%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)12.87%
Revenue growth 3Y17.67%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y